We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Feasibility and Outcomes of Hypofractionated Simultaneous Integrated Boost-Intensity Modulated Radiotherapy for Malignant Gliomas: A Preliminary Report.
- Authors
Jihye Cha; Chang-Ok Suh; Kwangwoo Park; Jong Hee Chang; Kyu Sung Lee; Se Hoon Kim; Jee Suk Chang; Joo Ho Kim; Yang-Gun Suh; Jun Won Kim; Jaeho Cho
- Abstract
Purpose: The aim of this study was to assess the feasibility and efficacy of hypo-fractionated simultaneous integrated boost-intensity modulated radiotherapy (SIB-IMRT) using three-layered planning target volumes (PTV) for malignant gliomas. Materials and Methods: We conducted a retrospective analysis of 12 patients (WHO grade IV-10; III-2) postoperatively treated with SIB-IMRT with concurrent temozolomide. Three-layered PTVs were contoured based on gadolinium-enhanced magnetic resonance imaging as follows; high risk PTV (H-PTV) as the area of surgical bed including residual gross tumor with a 0.5 cm margin; low risk PTV (L-PTV) as the area surrounding the high risk PTV with 1.5 cm margin; moderate risk PTV (M-PTV) as a line at one-third the distance from high risk PTV to low risk PTV. Total dose to high risk PTV was 70 Gy in 8 and 62.5 Gy in 4 patients. Results: The median follow-up time was 52 months in surviving patients. The 2- and 5-year overall survival (OS) rates were 66.6% and 47.6%, respectively. The 2- and 5-year progression-free survival (PFS) rates were 57.1% and 45.7%, respectively. The median OS and PFS were 48 and 31 months, respectively. Six patients (50%) progressed: in-field only in one, out-ield or disseminated in 4, and both in one patient. All patients completed planned treatments without a toxicity-related gap. Asymptomatic radiation necrosis was observed in 4 patients at post-radiotherapy 9-31 months. Conclusion: An escalated dose of hypofractionated SIB-IMRT using three-layered PTVs can be safely performed in patients with malignant glioma, and might contribute to better tumor control and survival.
- Subjects
FEASIBILITY studies; HEALTH outcome assessment; RADIOTHERAPY; RETROSPECTIVE studies; TEMOZOLOMIDE; GADOLINIUM; TUMOR treatment
- Publication
Yonsei Medical Journal, 2014, Vol 55, Issue 1, p70
- ISSN
0513-5796
- Publication type
Article
- DOI
10.3349/ymj.2014.55.1.70